Glucagon like peptide analogs, composition, and method of use
The present invention relates to novel analogs of glucagon like peptide and compositions that are useful for up-regulating insulin expression in mammals and for treating diabetes. In particular, these peptide derivatives have a peptide mimic linker and provides long duration of action for the treatment of diabetes and other insulinotropic peptide related diseases, gastrointestinal function and activities associated with glucagon levels.
1. A GLP-1 analog which is
[Q-Linker-c8, Glue22]GLP-1-(7-37)-peptide wherein Q-linker-c8 has the structure
2. A pharmaceutical composition comprising a GLP-1 analog of claim 1 and a pharmaceutically acceptable excipient.
3. The pharmaceutical composition according to claim 2 , wherein the pharmaceutical composition is suited for parenteral administration.
4. A method for preventing or treating hyperglycemia, type 2 diabetes, impaired glucose tolerance, type 1 diabetes, obesity, hypertension, syndrome X, dyslipidemia, cognitive disorders, atherosclerosis, myocardial infarction, coronary heart disease, stroke, inflammatory bowel syndrome, dyspepsia, or gastric ulcers in a subject, comprising administering to the subject in need thereof a therapeutically effective amount of a GLP-1 analog of claim 1 .
5. A method for preventing or delaying the progression of type 2 diabetes in a subject, comprising administering to the subject in need thereof a therapeutically effective amount of a GLP-1 analog of claim 1 .
6. A method for decreasing food intake, decreasing β-cell apoptosis, increasing β-cell function and β-cell mass, or restoring glucose sensitivity to β-cells in a subject, comprising administering to the subject in need thereof a therapeutically effective amount of a GLP-1 analog of claim 1 .